WGSWW — GeneDx Holdings Corp.

GeneDx Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q3 2025 revenues reached $116.7 million, a 52% increase year-over-year, driven by $98.9 million from exome and genome testing, up 66% from the previous year.
• Volume Growth: The company reported 25,702 exome and genome tests, with growth accelerating from 24% in Q1 to 33% in Q3.
• Adjusted Gross Margin: Expanded to 74%, attributed to favorable mix shifts and improved reimbursement rates.
• Adjusted Net Income: Reported at $14.7 million, translating to $0.51 adjusted EPS.
• Cash Position: As of September 30, 2025, cash and equivalents totaled $156 million.

2. Strategic Updates and Business Highlights

• Revenue Guidance: GeneDx raised its full-year 2025 revenue guidance to $425 million to $428 million.
• FDA Breakthrough Device Designation: The FDA granted breakthrough designation to ExomeDx and GenomeDx tests, validating their role in transforming rare disease diagnoses.
• Executive Hires: New appointments include Lisa Gurry as Chief Business Officer and Dr. Mimi Lee as Chief Precision Medicine Officer to enhance data diagnostics and partnerships.
• NICU Focus: Less than 5% of NICU patients currently receive genetic testing, presenting a significant growth opportunity. The company is on track to activate 12 Epic Aura integrations by year-end.
• Newborn Screening Initiatives: Participation in pivotal initiatives like the NIH Beacon program and Sunshine Genetics Network to drive clinical adoption of genomic medicine.

3. Forward Guidance and Outlook

• Exome and Genome Revenue Growth: Guidance for exome and genome revenues is set at 53% to 55% growth for 2025, with expectations for continued volume growth.
• Operational Investments: Anticipated sequential growth in operating expenses as the company builds its sales force and invests in customer experience and technology.
• Long-term Growth Strategy: The company aims to expand its market presence by targeting general pediatricians and enhancing its service offerings.

4. Challenges and Points of Concern

• Declining Hereditary Cancer Revenue: The discontinuation of hereditary cancer offerings is expected to reduce revenue contributions significantly, nearing $0 in Q4.
• Potential ASP Decline: Guidance implies a potential decrease in average selling prices (ASPs) due to initial lower payment rates from new call points.
• Operational Bottlenecks: Concerns about potential bottlenecks in genetic counseling as testing volumes increase, which could impact patient experience and service delivery.
• Investment Cycle: While investments are aimed at long-term growth, they may lead to short-term declines in EBITDA margins.

5. Notable Q&A Insights

• NICU Growth: The NICU market is identified as a fast-growing segment, with expectations of significant contributions to overall volume in the coming quarters.
• General Pediatrician Strategy: The company is focused on education and workflow improvements to facilitate adoption among general pediatricians, with a timeline of 18 to 24 months for meaningful volume increases.
• Medi-Cal Impact: The expansion of Medi-Cal coverage is expected to provide a significant revenue boost, transitioning from zero payments to an estimated 80% collection rate.
• Competitive Moat: GeneDx emphasizes its unique data set (Infinity) and AI capabilities, which are expected to enhance diagnostic accuracy and maintain competitive advantage.

Overall, GeneDx demonstrated strong growth in Q3 2025, with strategic initiatives aimed at expanding its market presence and enhancing service offerings, despite facing challenges related to pricing dynamics and operational scaling.